Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Segmentation:
Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc, Others)
Vitamin E and Pioglitazone segment is anticipated to account for more than 28.7% non-alcoholic steatohepatitis therapeutics and diagnostics market share by the end of 2035. This growth is attributed to their established efficacy in symptomatic alleviation of NASH and liver fibrosis reduction. Both therapies are considered cost-effective for their established clinical outcomes, which is boosting their adoption among healthcare providers. In May 2022, Pfizer Inc. announced that the FDA granted Fast Track designation to its investigational combination therapy for NASH with liver fibrosis, ervogastat (DGAT2 inhibitor) and clesacostat (ACC inhibitor). Such developments play a significant role in driving the demand for this drug type to fulfill unmet needs in the management of NASH.
End user (Hospital Pharmacies, Retail and Specialty Pharmacies, Others)
By 2035, retail and specialty pharmacies segment is projected to hold more than 49.2% non-alcoholic steatohepatitis therapeutics and diagnostics market share, driven by expanding access to advanced therapeutics. For such pharmacies, increasing access to innovative treatments has underlined their growing importance in the healthcare ecosystem. For example, the launch of Rezdiffra by Madrigal Pharmaceuticals in March 2024 further marked the retail and specialty pharmacies segment as a key player in delivering innovative therapies to patients. The specialty pharmacy is anticipated to garner rapid sales revenue as it provides tailored support and timely delivery for complex medications. Furthermore, their strategic positioning increases patient adherence to therapies and optimizes overall patient outcomes, which in turn drives the growth of the overall market.
Our in-depth analysis of the global non-alcoholic steatohepatitis therapeutics and diagnostics market includes the following segments:
|
Drug Type |
|
|
End user |
|
